Logotype for Niagen Bioscience Inc

Niagen Bioscience (NAGE) Q4 2019 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Niagen Bioscience Inc

Q4 2019 earnings summary

19 Nov, 2026

Executive summary

  • Q4 net sales rose 44% YoY to $13.1M; FY 2019 sales increased 47% to $46.3M, led by TRU NIAGEN.

  • FY 2019 exceeded guidance across key metrics, excluding the $2.2M Elysium receivable write-off.

Financial highlights

  • Q4 operating loss was $8.9M, including $2.2M of non-cash bad debt expense; excluding that item, operating loss was $6.7M.

  • FY operating loss was $31.3M reported and $29.1M excluding bad debt, a $4.1M improvement YoY on the latter basis.

  • FY net loss was $32.1M; Adjusted EBITDA excluding legal expense was a loss of $8.8M, improving $7.4M YoY.

Outlook and guidance

  • 2020 outlook: strong top-line growth, with moderate coronavirus impact in Q1; gross margin and Adjusted EBITDA excluding legal expected to improve.

  • Selling, marketing and advertising expense expected to rise $3–5M in absolute dollars but decline as a share of sales; G&A expected to rise $1–2M in absolute dollars.

  • Growth drivers include U.S. e-commerce, new markets including the U.K. and Australia, new platforms, returning customers, product cost savings and supply-chain efficiencies.

  • Cash-flow break-even framework remains unchanged; near-term operating expenses may rise due to litigation, with supply-chain savings targeted to support gross margins slightly above 60%.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Niagen Bioscience